By Fineline Cube 
Hansoh Pharmaceutical Group (HKG: 3692) released its interim results for the first half of 2026, reporting revenue of approximately RMB 8.30 billion, up 11.7% year on year, and profit of approximately RMB 4.26 billion, a 35.8% year‑on‑year increase. Innovative drug revenue reached approximately RMB 7.09 billion, representing 85.4% of total revenue, while the company executed its first Newco‑model out‑licensing transaction — a landmark in its internationalization strategy — and continued to expand its flagship EGFR‑TKI Ameile (almonertinib) globally.
Financial Highlights – 1H 2026
| Metric | 1H 2026 | YoY Change |
|---|---|---|
| Total Revenue | ~RMB 8.30 billion | +11.7% |
| Profit | ~RMB 4.26 billion | +35.8% |
| Innovative Drug Revenue | ~RMB 7.09 billion | 85.4% of total |
| Innovative Drug Product Sales Growth | — | +21.6% |
| Oncology Product Revenue | ~RMB 5.47 billion | 65.9% of total |
| R&D Expenditure | ~RMB 1.74 billion | +20.7% (~20.9% of revenue) |
Commercial Performance – Innovative Drugs & Ameile Franchise
- Innovation‑Driven Mix: Innovative drug revenue of approximately RMB 7.09 billion now accounts for 85.4% of total revenue, with innovative drug product sales growing approximately 21.6% year on year
- Oncology Anchor: Oncology products generated approximately RMB 5.47 billion, representing 65.9% of total revenue
- Ameile (almonertinib) Milestones:
- Now approved for five indications in lung cancer, continuing to achieve breakthroughs
- In 2026, successively approved for marketing in the European Union and the Macau Special Administrative Region of China, under the overseas brand name Aumseqa — extending the franchise beyond China
Pipeline Progress – 1H 2026 Execution
| Milestone | Count (Reporting Period) |
|---|---|
| Innovative drug clinical trials being advanced | 70+ (covering 40+ candidate innovative drugs) |
| New drug applications accepted for review | 3 |
| New Phase 3 pivotal registration trials initiated | 3 |
| New candidate innovative drugs receiving first‑time clinical trial approval | 4 |
Strategic Collaboration – HS‑20118 Newco Out‑Licensing
| Element | Detail |
|---|---|
| Asset | HS‑20118, IL‑23 receptor antagonist |
| Partner | Avere Therapeutics (overseas rights) |
| Transaction Value | Exceeding USD 2.3 billion total |
| Deal Date | June 2026 |
| Follow‑On Event | Avere merged with NextCure, Inc. (Nasdaq: NXTC) in July 2026 |
| Strategic Significance | Hansoh’s first Newco model out‑licensing transaction |
The HS‑20118 transaction marks Hansoh Pharma’s first adoption of the Newco model for out‑licensing, demonstrating a more diversified and mature internationalization path that balances upfront economics with retained upside through the Nasdaq‑listed successor entity.
Market Impact & Outlook
- Profit Quality Inflection: Profit growth of 35.8% outpacing 11.7% revenue growth reflects operating leverage from the 85.4% innovative‑drug mix, validating Hansoh’s transformation from generic‑heavy to innovation‑driven.
- Ameile Globalization: EU and Macau approvals under the Aumseqa brand establish almonertinib as a genuinely international third‑generation EGFR‑TKI, with further geographic expansion as the key commercial catalyst.
- Newco Model Precedent: The USD 2.3 billion HS‑20118 deal and subsequent Avere–NextCure merger create a replicable template for Hansoh to monetize overseas rights across its 40+ candidate innovative drugs.
- Watch Items: Three NDAs under review, three new Phase 3 readouts as they mature, HS‑20118 clinical progression under the merged NextCure entity, and further out‑licensing transactions building on the Newco precedent.
Forward‑Looking Statements – This brief is for informational purposes only and does not constitute investment advice. Interim results are as reported by the Company; statements regarding pipeline development, approvals, and future financial performance are forward‑looking and subject to risks and uncertainties; actual results may differ materially. Refer to official announcements and filings from Hansoh Pharmaceutical Group for authoritative details.-Fineline Info & Tech